WS #16430
The Trump administration has reversed its stance on a proposed ban of kratom, a natural opioid substitute, following intense lobbying from the industry. This regulatory de-escalation removes a significant overhang on cannabis and alternative pain-management stocks, signaling a more pragmatic approach to substance regulation that could benefit companies with exposure to these sectors.
Kratom Regulatory Reversal
The Trump administration has reversed its stance on a proposed ban of kratom, a natural opioid substitute, following intense lobbying from the industry. This regulatory de-escalation removes a significant overhang on cannabis and alternative pain-management stocks, signaling a more pragmatic approach to substance regulation that could benefit companies with exposure to these sectors.